Shroom With a View: Strains, Chocolate Bars, and What Psilocybin Really Does to Your Brain, Now and Years Later

Psilocybin is a prodrug: the body converts it into active psilocin. That chemistry is fairly clear. A mushroom name or chocolate wrapper is not. It cannot establish species, amount, purity, identity, or how one person will respond.

“Golden Teacher.” “Penis Envy.” A foil wrapper with a cartoon cap. These names feel informative because they are memorable. They are not standardized pharmaceutical identities.

When research is promising, the distinction becomes more important, not less. A screened clinical trial of a known investigational drug is not a safety certificate for a wild mushroom, a home-grown batch, or a branded edible.

What matters most

• Popular cultivar names do not reliably predict psilocybin content or personal response. Small chemistry studies show variation between labels, individual mushrooms, and storage conditions.
• Blue bruising, a photograph, an app, or an online comment cannot rule out a deadly look-alike. Unknown wild-mushroom ingestion deserves prompt Poison Control guidance.
• Amanita muscaria is not a psilocybin mushroom. Its principal psychoactive chemistry and toxic effects are different.
• Cell, mouse, and brain-imaging findings suggest plasticity and network change. They do not prove permanent healing, personality improvement, or protection from relapse.
• COMP360 phase 3 toplines were positive by sponsor report, but full results were not yet peer reviewed and FDA had not approved the product as of September 3, 2026.

Zoom

Species, cultivars, and the marketing word “strain”

Psilocybe cubensis is one species that contains psilocybin and psilocin. Names such as Golden Teacher, B+, and Penis Envy usually describe cultivation lineages, seller categories, or market reputation. They do not come with a regulator-enforced genetic identity, chemical specification, or dose consistency.

Variation exists at several levels:

• Between species: Different psilocybin-containing species can differ in chemistry, habitat, appearance, and look-alike risk.
• Within a species: Genetics and growing conditions can change alkaloid production.
• Within a named cultivar: A label can cover different lineages, conditions, and seller practices.
• Between individual mushrooms: Caps, stems, developmental stage, and individual specimens may differ.
• After harvest: Heat, light, oxygen, moisture, storage time, and processing can change measured content.

Gotvaldová and colleagues studied how fungal part, processing, and storage affected tryptamine content; the work did not validate named-cultivar potency rankings.1 A 2024 analysis examined only five commercial labels, with three intact mushrooms per label. Average total psilocybin plus psilocin ranged from 0.879% to 1.36% by dry weight, with between-label and within-label variation.2 That is useful evidence of inconsistency, not a consumer potency chart.

A 2026 controlled analysis of 14 named P. cubensis lines reported total tryptamines ranging from 2.62 to 20.65 mg per gram, more than a 7.8-fold spread.3 Controlled growing conditions strengthen the chemistry comparison, but the findings still do not turn market names into standardized products or tell a reader what is in a package.

Some wild species are discussed online as stronger or different from cultivated ones. The clinically important point is not a ranking. It is that species identification is difficult, chemistry varies, and a naming mistake can become poisoning.

There is also a measurement problem. Researchers may report psilocybin alone, psilocin alone, their sum, or a wider tryptamine profile. Fresh and dried weight are not interchangeable. Grinding several mushrooms can average variation while testing one exposes it. Analytical precision does not fix an uncertain sample name. A laboratory can accurately measure the item it received while saying nothing about the next item in the same-looking bag.

The language of “strain effects” often goes beyond chemistry into promises that one label is visual, another social, and another spiritual. Controlled evidence has not validated those personality profiles. Expectation and setting can shape experience, but that does not make a commercial description a reproducible pharmacologic property.

Wild picking can turn into poisoning

Some deadly mushrooms grow near species people seek. Galerina marginata, for example, can contain amatoxins that cause delayed liver failure. Early gastrointestinal symptoms may improve before severe organ injury becomes apparent. Waiting for certainty can waste the treatment window.4

Blue bruising is not a reliable safety test. A phone app, photograph, spore-print anecdote, or one online opinion cannot exclude a dangerous look-alike. This article will not provide a field key because partial identification instructions can create false confidence.

After any suspected wild or unknown mushroom ingestion in the United States, call Poison Control promptly at 1-800-222-1222, even before severe symptoms develop. Save a sample and photographs if doing so is safe, but do not delay care while posting online. Do not induce vomiting unless Poison Control or a clinician instructs it.5

Call 911 for collapse, seizure, inability to wake, trouble breathing, severe confusion, dangerous behavior, severe chest symptoms, or immediate danger.

Amatoxin poisoning is especially deceptive because serious liver injury can develop after a symptom-free interval. A person should not cancel Poison Control or emergency advice because vomiting stopped or they feel better. Clinicians may need time-sensitive laboratory monitoring and treatment before the full injury is obvious.

Children and pets face different risk from body size, communication limits, and delayed discovery. Store any mushroom or edible locked away and in packaging that does not resemble ordinary candy. If a child may have eaten one, call Poison Control promptly instead of waiting for behavior to change.

Amanita is not psilocybin

Amanita muscaria, the red-and-white mushroom used in familiar illustrations, does not produce a classic psilocybin state. Its important compounds include muscimol and ibotenic acid. Muscimol acts at GABA-A receptors, while ibotenic acid has excitatory effects and can be converted to muscimol. Effects can be sedating, agitating, delirium-like, dissociative, or mixed.

Vomiting, confusion, loss of coordination, unusual behavior, profound sleepiness, agitation, and seizures can occur. Product processing is variable. A gummy sold as “Amanita” may not match the named species or declared chemicals.

FDA stated that Amanita muscaria, its extracts, muscimol, ibotenic acid, and muscarine are not authorized for use as conventional food ingredients and may be harmful.6 Open sale does not establish lawful food use, accurate labeling, or safety.

The gray-market chocolate and gummy problem

A polished box is not a chain of custody. QR codes can point to recycled or irrelevant certificates. Identical wrappers can be bought empty. A laboratory-looking report may describe one submitted sample, not the item in hand or every unit in a batch.

In a 2025 peer-reviewed analysis, researchers bought 12 products marketed as magic mushroom edibles from Portland, Oregon: 11 gummies and one chocolate. They detected no psilocybin in any, including one gummy labeled as containing 100 mg per piece. The authors reported that seven of the 12 products contained undisclosed ingredients: synthetic tryptamines, cannabinoids, kava-related compounds, caffeine, or psilocin without the precursor compounds a real mushroom would carry. Four gummies contained no detected active ingredient at all.7

That means most of the selected products either hid an undeclared active or delivered nothing. It does not mean the same proportions hold for every U.S. product. This was a small convenience sample from one city at one time.

Diamond Shruumz: one brand, many findings

The 2024 Diamond Shruumz recall and outbreak provides a stronger national warning about product uncertainty. The final CDC report, published in April 2026, counted 180 moderate or major poisoning cases across 34 states among people who ate a Diamond Shruumz product or another mushroom-containing chocolate product, including 73 hospitalizations, 38 ICU admissions, 29 intubations, and two associated deaths. Of those 180 cases, 118 (66%) involved a Diamond Shruumz product, and about a third involved chocolate products of other or unknown brands. Eating Diamond Shruumz chocolate bars carried significantly higher odds of seizure, hospitalization, ICU admission, and intubation than eating other mushroom chocolate products, and severity rose with the amount eaten.8

FDA testing found different substances in different samples, including muscimol, psilocin, acetylpsilocin, kavalactones, and pregabalin.9 Severe effects included seizures, loss of consciousness, abnormal heart rate or blood pressure, agitation, nausea, vomiting, and confusion. The investigation did not establish that one ingredient caused every illness or either associated death.

The date and wording matter. Case counts climbed through 2024 as the investigation ran. FDA’s outbreak page, last updated November 15, 2024, still lists three potentially associated deaths, while CDC’s peer-reviewed 2026 report describes two deaths associated with the outbreak.9 A reader who sees different numbers on different official pages is not seeing an error. They are seeing an investigation that was still resolving which deaths met the case definition. One outbreak also does not prove every mushroom edible has the same contents. It proves that a food-like product can conceal a medically important mixture.

Batch-specific findings resist a single villain story. Muscimol in one sample does not explain psilocin in another or pregabalin in another. Clinical effects may reflect a detected ingredient, an undetected ingredient, a combination, dose variation, or a person’s health. The public-health conclusion is strong even when the molecule-by-molecule causal map is incomplete.

Retail availability can create an illusion of regulatory review. A product can sit on a shelf because enforcement is fragmented or because the seller makes claims that have not yet been tested. Neither route is FDA approval. “Made in a facility” does not identify the active drug, and “proprietary blend” can hide the information needed during an emergency.

For clinicians and families, the package, receipt, and lot number may help Poison Control or public-health investigators if they can be saved safely. They should never delay 911. No one should taste, smell, or handle remaining unknown material in an attempt to diagnose the exposure.

What psilocin does in the brain

After ingestion, alkaline phosphatase removes a phosphate group from psilocybin, producing psilocin. Psilocin acts principally as a serotonin 5-HT2A receptor agonist, with other targets involved. Activity at 5-HT2A receptors on cortical layer V pyramidal neurons is one important mechanistic lens, not a complete explanation.101112

At the network level, imaging studies report altered communication within and between brain networks, including changes involving the default-mode network. A 2024 human study found acute desynchronization and changes linking the hippocampus and default-mode network that could still be detected weeks later.13 A small 2026 placebo-controlled study in 28 healthy, entirely psychedelic-naive adults reported anatomical changes on diffusion imaging one month after a single 25 mg dose, while enduring functional brain changes were largely absent.14

These are measurements, not a photograph of insight. Network disruption does not automatically mean a harmful brain was reset. A persistent imaging signal does not prove durable clinical recovery.

The entropic-brain model proposes that psychedelics increase the diversity or unpredictability of brain activity, loosening strongly held patterns. It is a model that helps organize findings. It is not a settled account of consciousness or a guarantee that loosened patterns become healthier.

Perception, time, emotion, body boundaries, and sense of self can change. In research, an oral experience is often described as a four-to-six-hour arc, with variability and possible lingering fatigue or emotional sensitivity. That range is provided for safety awareness, not for planning use.

Acute subjective intensity varies even under controlled conditions. A person may feel awe, fear, grief, confusion, or several states in sequence. “Ego dissolution” is an experience and research term, not proof that a damaged self was repaired. A strongly meaningful memory can still be inaccurate, and confidence in an insight does not establish its truth.

This is one reason psychological support matters in trials. Staff monitor vital signs and behavior, orient a distressed participant, reduce environmental hazards, and follow symptoms afterward. Support does not eliminate all risk. It changes what can be recognized and treated.

Neuroplasticity: promising finding, easy overclaim

In 2018, Ly and colleagues found structural and functional plasticity effects from psychedelics in cell and animal models.15 In 2021, Shao and colleagues observed increased dendritic-spine formation in mice after psilocybin, with some changes persisting for about a month.16

Neither study showed a person’s trauma healing, depression lifting, or personality permanently improving. Cells are not patients. A mouse spine is not a relationship, a relapse, or a life.

Human trials can ask clinical questions, but expectancy, imperfect blinding, intensive support, selected participants, and short follow-up remain important. Plasticity may create a period in which learning or context matters more. That statement is still a hypothesis about how clinical benefit might occur, not a reason to assume that any intense experience is therapeutic.

The direction of learning matters. A flexible period paired with preparation, safety, and follow-up may differ from an unknown exposure during sleep deprivation, conflict, or panic. Plasticity is not automatically beneficial. Brains also learn fear, avoidance, and overconfident explanations. Research must connect mechanism to measured clinical function, not only to an appealing image of new connections.

Short-term and interaction risks

Panic, confusion, vomiting, falls, traffic exposure, unsafe behavior, and prolonged distress can occur. Heart rate and blood pressure may rise. The environment can become hazardous when perception and judgment change.

People with active psychosis, schizophrenia-spectrum illness, bipolar I disorder, current mania, or severe uncontrolled medical illness are commonly excluded from modern trials and face a strong warning against unsupervised use. A first-degree family history of bipolar or psychotic illness is a high-caution category with poorly quantified risk, not proof that one person will have an episode.17

Lithium is a serious signal, not a known percentage risk

An analysis of online experience reports found seizures in 47% of 62 reports involving lithium plus a classic psychedelic, and medical attention in 39%.18 These were highly selected, self-reported accounts. They cannot estimate incidence, prove causality, confirm every substance, or show what happens to typical patients. The severity of the signal still warrants a clear warning.

Do not stop lithium to take psilocybin. Abrupt changes can destabilize bipolar disorder, and no washout period in an article can make an unknown product safe. Contact the prescriber after any exposure or before considering participation in legitimate research.

Antidepressants and other medicines

Controlled and observational findings on SSRIs and SNRIs are mixed. Some evidence suggests attenuated psychedelic effects; other reports find less or variable blunting. Interaction evidence is incomplete.19 Do not stop an antidepressant to intensify an experience. Discontinuation can produce withdrawal, relapse, suicidality, or mood destabilization.

Rapid tolerance and low classic physical-dependence potential are often described for psilocybin. Those features do not protect against injury, panic, mania, psychosis, mislabeled products, or compulsive patterns around seeking experiences.

Medical risk is not limited to a receptor interaction. Vomiting can lead to aspiration in a deeply impaired person. Falls and traffic can cause head injury. Severe agitation may produce restraint-related or heat risk. A person with uncontrolled blood pressure or cardiac disease may not resemble a screened trial participant. When symptoms are concerning, exact product identification can wait while breathing, circulation, temperature, and safety are addressed.

What may last

Some people report lasting positive changes in mood, meaning, behavior, or well-being after a psychedelic experience. Others report anxiety, derealization, distress, perceptual symptoms, mania, or psychosis. Screened trials and selected surveys do not represent every community exposure.

HPPD refers to persistent or recurring perceptual disturbance after hallucinogen exposure. It appears uncommon, but definitions and denominators are uncertain. Persistent psychosis or mania is also reported, yet psilocybin-specific incidence is not known. “Rare” should not be converted into “impossible.”

Johansen and Krebs analyzed population survey data in 2015 and did not find an association between lifetime psychedelic use and several mental-health outcomes.20 The study was cross-sectional, relied on self-report, could not control every difference between users and nonusers, and could not rule out rare harms. Failure to find an association is not proof of universal safety.

A systematic review of long-term psychedelic effects found possible enduring positive and negative changes but emphasized heterogeneous designs, selected samples, and limited causal inference.21 Later registry and cohort studies remain vulnerable to self-selection and expectancy. The most defensible conclusion is that durable change can occur in more than one direction and cannot be promised.

Follow-up studies also face a denominator problem. People with a memorable benefit or serious difficulty may be more likely to answer surveys. People who are hospitalized, disengaged, or embarrassed may be missed. Trials can collect adverse events systematically, but they often exclude people thought to be at higher risk and may not be powered to detect rare outcomes. Community surveys include broader exposure but often cannot verify the drug.

Persistent visual symptoms should be evaluated rather than diagnosed from a checklist. Migraine, seizure disorders, eye disease, medication effects, anxiety, sleep deprivation, and other neurologic conditions can overlap. Likewise, insomnia and intense spiritual or grandiose ideas after exposure may represent a mood episode needing prompt care, not merely “integration.”

Clinical trials are a different product and setting

A modern trial generally uses a standardized investigational product, verified dose, medical and psychiatric screening, preparation, trained monitoring, psychological support, follow-up, and systematic adverse-event collection. Common exclusions limit how results generalize to bipolar I disorder, psychotic illness, unstable medical disease, pregnancy, and some medication combinations.

Phase 2 trials, one with 233 and one with 104 participants, have found promising effects in depression, including treatment-resistant depression and major depressive disorder.2223 Participants knew they might receive a psychedelic, acute effects can reveal assignment, and follow-up was limited. Support around the drug is part of the studied package even when the exact role of psychotherapy is debated.

In the 2022 treatment-resistant-depression study, a higher tested COMP360 dose produced a larger short-term symptom reduction than a very low control dose, but adverse events and suicidal behavior required careful interpretation in a high-risk population.22 The 2023 major-depression trial also reported improvement after a single supported session. Neither trial answered whether a retail mushroom, repeated unsupervised exposure, or a person excluded for mania or psychosis risk would share the outcome.

Blinding is unusually difficult because the acute state can reveal assignment to participants and staff. Low-dose controls and active placebos may reduce expectancy but cannot erase it. Depression scores can improve meaningfully while questions about durability, retreatment, therapist effects, functional recovery, and rare harms remain.

COMP360 status checked 2026-09-03

COMP360 is a proprietary synthetic psilocybin formulation under study for treatment-resistant depression. ClinicalTrials.gov lists two pivotal phase 3 programs, COMP005 and COMP006.24

The sponsor reported that COMP005 enrolled 258 participants and that a single 25 mg dose produced a week-six mean MADRS treatment difference of -3.6 points versus placebo, 95% CI -5.7 to -1.5. For COMP006, the sponsor reported that two 25 mg administrations three weeks apart produced a week-six mean difference of -3.8 points versus a 1 mg control, 95% CI -5.8 to -1.8. Both toplines were reported as p less than 0.001.2526

These are sponsor-reported topline results. As of September 3, 2026, neither COMP005 nor COMP006 had been published in a peer-reviewed journal. FDA granted the sponsor’s request for a rolling new-drug-application submission and review in April 2026 and selected COMP360 for the Commissioner’s National Priority Voucher program. FDA describes that program as targeting a review of roughly one to two months, against six months or more for a standard review, and states that applications selected for it remain subject to the same statutory and regulatory requirements for approval as applications outside the program.27 The sponsor reported in July 2026, and again in its August 5, 2026 quarterly update, that the rolling submission was still underway, with final submission expected in the fourth quarter of 2026 and a possible launch in the first half of 2027 only if FDA approves and DEA reschedules.28 FDA had not approved COMP360 by September 3, 2026, no advisory committee meeting had been scheduled, and no decision date had been set. Breakthrough Therapy designation, a priority voucher, and rolling review speed a process. They do not establish approval, efficacy for every patient, or equivalence to a retail bar.

Regulatory review asks questions beyond whether the primary endpoint crossed a statistical threshold. FDA can examine manufacturing consistency, acute monitoring, therapist or facilitator roles, abuse-related risk, suicidality, longer follow-up, labeling, and whether benefits outweigh harms in the intended population. A positive trial can support an application without predetermining the decision.

If approval eventually occurs, the label and any required risk-management system will define the medical product. It would not automatically legalize mushrooms, validate unlicensed facilitators, or transform commercial gummies into generic versions. Synthetic psilocybin, a mushroom, and a mystery edible can share a word while remaining different clinical and regulatory objects.

Microdosing: a confident culture, an uncertain benefit

Microdosing generally means taking a sub-perceptual or minimally perceptible amount repeatedly. There is no universally accepted definition, and this article will not provide a schedule.

In a 2021 self-blinding citizen-science study with 191 participants, both active and placebo groups improved on several measures. Guessing assignment and expectation complicated interpretation.29 Later blinded studies and a 2026 umbrella review have not established reliable cognitive enhancement. In that review, the only significant pooled effect ran opposite to popular claims: a small but consistent decrease in cognitive control, d = -0.34, 95% CI -0.62 to -0.06. Self-reported mood benefits were largely absent once trials were placebo controlled. Short-term tolerability appeared acceptable, but cardiovascular signals and long-term risk remain uncharacterized.30

It is too broad to say every benefit is “just placebo.” It is equally unsupported to promise focus, creativity, or antidepressant benefit. Product identity, repeated exposure, interaction, and legal risks remain even when an intended amount is small.

Microdosing studies also struggle to verify what participants take outside a laboratory. A person may follow a personal routine precisely while using a chemically variable product. Repeated self-observation can itself change mood or behavior. The scientific need is for larger blinded studies with verified compounds and longer follow-up, not certainty in either direction.

The under-25 question

This section states general clinical framing rather than psilocybin-specific findings, because the psilocybin-specific developmental research does not yet exist. Brain maturation is commonly described as continuing into the mid-to-late twenties, without a birthday cutoff. That same period overlaps with the typical age of onset for bipolar and psychotic disorders, with changing sleep schedules, experimentation, and social risk. Overlap in timing does not establish causation in either direction.

Psilocybin-specific developmental evidence is sparse. Cannabis findings cannot simply be transferred to mushrooms. A young person’s personal and family psychiatric history, other substances, medication, sleep loss, and setting may matter, but no study supports saying one exposure permanently changes every young brain.

Developmental uncertainty cuts both ways. It does not prove unique permanent harm from one psilocybin exposure, and it does not justify assuming adult trial findings apply to adolescents. Most treatment trials enroll adults under controlled conditions. Prevention language should be honest about that gap while remaining clear about product, psychiatric, injury, and legal risks.

Uncertainty is a reason for proportionate caution, not for invented certainty.

It also supports early assessment when symptoms persist.

Early care can prevent avoidable delay.

For a young person with days of reduced sleep, racing thoughts, paranoia, unusual certainty, hallucinations, or a sharp functional change after exposure, the priority is prompt assessment. Waiting to decide whether it is “just the drug” can allow a treatable mood or psychotic episode to worsen.

Legal status checked 2026-09-03

• Federal: Psilocybin and psilocin remained Schedule I controlled substances under 21 CFR 1308.11(d). No psilocybin or psilocin product was FDA approved.31 Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, signed April 18, 2026, directed the FDA Commissioner to provide Commissioner’s National Priority Vouchers to psychedelic drugs that have received a Breakthrough Therapy designation, directed FDA and the Drug Enforcement Administration to establish a pathway for eligible patients to access psychedelic drugs under the Right to Try Act, and directed the Attorney General to review any Schedule I product that has successfully completed phase 3 trials for a serious mental health disorder so that rescheduling, if appropriate, may proceed. The order rescheduled nothing and approved no product by itself.32
• Oregon: Adults age 21 or older can access psilocybin services through licensed service centers after preparation and under licensed supervision. Oregon did not create ordinary retail sales or a take-home market, and federal law remains unchanged.33
• Colorado: State law created regulated natural-medicine healing centers and facilitators, alongside defined personal-use allowances for adults 21 or older. Implementation and rules continue to evolve, and federal law remains unchanged.34
• California: Psilocybin remained Schedule I under state law, and possession, cultivation, sharing, and sale could still trigger state or federal consequences. AB 1103 was signed on October 10, 2025 (Chapter 571, Statutes of 2025) and lets the state Research Advisory Panel expedite review of Schedule I and II research projects until January 1, 2028. It did not legalize personal or retail access. Two research bills, AB 2489 and SB 1224, stalled on the Appropriations suspense file and did not reach a floor vote before the 2026 deadline. Neither would have created personal or retail access.3536
• Local California examples: Santa Cruz, Arcata, and Berkeley adopted varying resolutions that deprioritize some enforcement involving entheogenic plants or fungi. Santa Cruz first acted in January 2020, then rescinded and replaced that resolution in September 2021 to exclude peyote and other mescaline-containing cacti. Arcata adopted Resolution 212-17 in October 2021. Berkeley adopted Resolution 70,962-N.S. in July 2023, limited to naturally occurring plants and fungi and still barring giving away, sharing, or distributing them.373839 These three verified examples are not a complete California survey. Their policies differ and do not create statewide or federal legality.

Law changes. Local deprioritization is not legalization, a retail license, or protection from every consequence. This is not legal advice.

Product and setting comparison

When to call 911 after a mushroom or edible exposure

Call 911 for inability to wake, seizure, severe confusion or dangerous behavior, breathing trouble, blue or gray lips, collapse, severe chest symptoms, or immediate danger.

Call Poison Control promptly at 1-800-222-1222 after any suspected wild or unknown mushroom ingestion, any child ingestion, or a concerning mislabeled-product exposure, even before severe symptoms develop. Do not induce vomiting unless Poison Control or a clinician directs it. Do not delay care while trying to identify a mushroom online.5

Frequently asked questions

Are Golden Teacher and Penis Envy reliable dose labels?

No. They are cultivation or market names, not regulated chemical specifications. Content varies between labels, mushrooms, conditions, storage, and processing.

Does blue bruising prove a mushroom is psychedelic?

No. Bruising cannot establish species, exclude a deadly look-alike, or prove safety. Contact Poison Control after an unknown wild-mushroom ingestion.

Are mushroom chocolate bars real psilocybin?

Some may contain psilocin or psilocybin, while others contain synthetic tryptamines, cannabinoids, Amanita compounds, medicines, mixtures, or no expected drug. Packaging cannot authenticate the item.

Can psilocybin trigger bipolar mania or psychosis?

Mania and psychosis have been reported, but incidence is poorly quantified. People with active psychosis, bipolar I disorder, or current mania are commonly excluded from trials and face a strong warning against unsupervised use.

Is psilocybin legal in California?

Not statewide for ordinary possession, cultivation, sharing, sale, or retail treatment. Some cities have deprioritized enforcement, but that is not state or federal legalization. Law should be rechecked for a specific situation.

The distinction that matters most

Promising research on a known investigational drug, in a screened and monitored setting, is not a safety certificate for an unknown mushroom or branded edible. When a substance is uncertain, recognize the emergency rather than trusting the wrapper. For the broader party-drug comparison, testing limits, and naloxone response, see Rave New World.

This article is education, not medical or legal advice. It does not provide doses, cultivation, field identification, medication washouts, or a way to certify a mushroom or retail product as safe.

Related reading on NP FADY

• Rave New World: What Molly, Acid, DMT, and Edibles Actually Do Inside Your Brain
• Psilocybin: A Once-Sacred Mushroom Making Its Way Into Modern Medicine

References

1. Gotvaldová K, Hájková K, Borovička J, Jurok R, Cihlářová P, Kuchař M. Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis. Drug Test Anal. 2021;13:439-446. https://pubmed.ncbi.nlm.nih.gov/33119971/

2. Goff R, Smith M, Islam S, et al. Determination of psilocybin and psilocin content in multiple Psilocybe cubensis mushroom strains using liquid chromatography and tandem mass spectrometry. Anal Chim Acta. 2024;1288:342161. https://pubmed.ncbi.nlm.nih.gov/38220293/

3. Sharchaton A, Parsha S, Azerrad SP, Dekel Y, Rabah N, Páleníček T, Kurzbaum E. Surprising variability in tryptamine profiles of Psilocybe cubensis fruiting bodies: inter- and intra-strain differences across 14 strains cultivated under controlled conditions. J Fungi. 2026;12(7):486. https://www.mdpi.com/2309-608X/12/7/486

4. Diaz JH. Amatoxin-containing mushroom poisonings: species, toxidromes, treatments, and outcomes. Wilderness Environ Med. 2018;29(1):111-118. https://journals.sagepub.com/doi/10.1016/j.wem.2017.10.002

5. America’s Poison Centers. Get Poison Help. https://poisoncenters.org/get-poison-help ; National Capital Poison Center. First aid: Act fast! https://www.poison.org/first-aid-for-poisonings

6. U.S. Food and Drug Administration. FDA alerts industry and consumers about the use of Amanita muscaria or its constituents in food. Constituent Update, December 18, 2024. https://www.fda.gov/food/hfp-constituent-updates/fda-alerts-industry-and-consumers-about-use-amanita-muscaria-or-its-constituents-food

7. van Breemen RB, Simchuk D, Fritzsche B, Huson D, Kuzdzal SA, Ferguson J. Active constituents of psilocybin mushroom edibles. JAMA Netw Open. 2025;8(9):e2531345. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2838765

8. Rumph JT, Winquist A, Troeschel AN, et al. Severe illness associated with eating mushroom-containing chocolate products, United States, January to October 2024. MMWR Morb Mortal Wkly Rep. 2026;75(13):179-184. https://www.cdc.gov/mmwr/volumes/75/wr/mm7513a2.htm

9. U.S. Food and Drug Administration. Investigation of illnesses: Diamond Shruumz-brand chocolate bars, cones, and gummies (June 2024). Last updated November 15, 2024. https://www.fda.gov/food/outbreaks-foodborne-illness/investigation-illnesses-diamond-shruumz-brand-chocolate-bars-cones-gummies-june-2024

10. National Institute on Drug Abuse. Psychedelic and Dissociative Drugs. https://nida.nih.gov/research-topics/psychedelic-dissociative-drugs

11. Adeyinka D, Forsyth D, Currie S, Faraone N. Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. Front Syst Neurosci. 2025. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2025.1585367/full

12. Schmitz GP, Chiu YT, Foglesong ML, et al. Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation. Transl Psychiatry. 2025. https://www.nature.com/articles/s41398-025-03611-0

13. Siegel JS, et al. Psilocybin desynchronizes the human brain. Nature. 2024. https://www.nature.com/articles/s41586-024-07624-5

14. Lyons T, Spriggs M, Kerkelä L, et al. Human brain changes after first psilocybin use. Nat Commun. 2026. https://www.nature.com/articles/s41467-026-71962-3 ; lay summary: University of California, San Francisco. One Dose of Psilocybin Changes the Human Brain. 2026. https://www.ucsf.edu/news/2026/05/431866/one-dose-psilocybin-changes-human-brain

15. Ly C, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. 2018;23:3170-3182. https://pubmed.ncbi.nlm.nih.gov/29898390/

16. Shao LX, Liao C, Gregg I, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535-2544.e4. https://pmc.ncbi.nlm.nih.gov/articles/PMC8376772/

17. Downey AE, Bradley ER, Lerche AS, O’Donovan A, Krystal AD, Woolley J. A plea for nuance: should people with a family history of bipolar disorder be excluded from clinical trials of psilocybin therapy? Psychedelic Med. 2024;2(2):61-73. https://pmc.ncbi.nlm.nih.gov/articles/PMC11658676/

18. Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports. Pharmacopsychiatry. 2021;54:240-245. https://pubmed.ncbi.nlm.nih.gov/34348413/

19. Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology. 2022;239:1945-1976. https://pmc.ncbi.nlm.nih.gov/articles/PMC9177763/

20. Johansen PØ, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29:270-279. https://pubmed.ncbi.nlm.nih.gov/25744618/

21. Aday JS, et al. Long-term effects of psychedelic drugs: a systematic review. Neurosci Biobehav Rev. 2020;113:179-189. https://pubmed.ncbi.nlm.nih.gov/32194129/

22. Goodwin GM, et al. Single-dose psilocybin for treatment-resistant depression. N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/36322843/

23. Raison CL, et al. Single-dose psilocybin treatment for major depressive disorder. JAMA. 2023. https://pubmed.ncbi.nlm.nih.gov/37651119/

24. ClinicalTrials.gov. NCT05624268 (COMP005) and NCT05711940 (COMP006). https://clinicaltrials.gov/study/NCT05624268 ; https://clinicaltrials.gov/study/NCT05711940

25. Compass Pathways. COMP005 phase 3 topline results. 2025. https://ir.compasspathways.com/News—Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

26. Compass Pathways. COMP006 phase 3 topline results. 2026. https://ir.compasspathways.com/News—Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx

27. Compass Pathways. Compass Pathways announces FDA granted NDA rolling review request and awarded Commissioner’s National Priority Voucher. 2026-04-24. https://ir.compasspathways.com/News—Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx ; U.S. Food and Drug Administration. Commissioner’s National Priority Voucher (CNPV) Pilot Program. https://www.fda.gov/industry/commissioners-national-priority-voucher-cnpv-pilot-program

28. Compass Pathways. Six-month COMP006 results and rolling NDA status. 2026-07-07. https://ir.compasspathways.com/News—Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/

29. Szigeti B, et al. Self-blinding citizen science to explore psychedelic microdosing. eLife. 2021. https://elifesciences.org/articles/62878

30. Ozaydin Y, Canlan Ozaydin B. Classical psychedelic microdosing, mood, and cognitive function: an umbrella review with narrative synthesis. J Psychopharmacol. 2026;40(7):1091-1102. https://pubmed.ncbi.nlm.nih.gov/42365488/

31. Code of Federal Regulations. 21 CFR 1308.11(d), Schedule I. https://www.ecfr.gov/current/title-21/section-1308.11 ; U.S. Drug Enforcement Administration. Psilocybin Fact Sheet (lay reference). https://www.dea.gov/factsheets/psilocybin

32. Executive Order 14401 of April 18, 2026. Accelerating Medical Treatments for Serious Mental Illness. 91 FR 21709, April 22, 2026. https://www.federalregister.gov/documents/2026/04/22/2026-07907/accelerating-medical-treatments-for-serious-mental-illness ; The White House. Presidential Actions, Accelerating Medical Treatments for Serious Mental Illness. https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/

33. Oregon Health Authority. Oregon Psilocybin Services. https://www.oregon.gov/oha/ph/preventionwellness/pages/psilocybin-access-psilocybin-services.aspx

34. Colorado Department of Regulatory Agencies. Natural Medicine, facilitator licensing. https://dpo.colorado.gov/NaturalMedicine ; Colorado Department of Revenue, Natural Medicine Division, healing centers. https://nmd.colorado.gov/

35. California Legislature. Bill status, AB 1103, AB 2489, and SB 1224, 2025 to 2026 session. https://leginfo.legislature.ca.gov/faces/billStatusClient.xhtml?bill_id=202520260AB1103 ; https://leginfo.legislature.ca.gov/faces/billStatusClient.xhtml?bill_id=202520260AB2489 ; https://leginfo.legislature.ca.gov/faces/billStatusClient.xhtml?bill_id=202520260SB1224

36. California Legislature. Health and Safety Code sections 11054 and 11377. https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=HSC&sectionNum=11054 ; https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=HSC&sectionNum=11377

37. City of Santa Cruz. Resolution Related to Adult Personal Use and Possession of Entheogenic Plants and Fungi. https://ecm.cityofsantacruz.com/OnBaseAgendaOnline/Documents/ViewDocument/Summary_Sheet_for_-_Resolution_Related_to_Adult_Personal_Use_and_Personal_Possession_of_Entheogenic_?documentType=Agenda&isSection=false&itemId=17321&meetingId=1760&publishId=22849

38. City of Arcata. Resolution 212-17, Entheogenic Plants and Fungi. 2021. https://pub-arcata.escribemeetings.com/filestream.ashx?documentid=9642

39. City of Berkeley. Annotated Agenda, July 11, 2023, adopting Resolution No. 70,962-N.S. https://berkeleyca.gov/sites/default/files/city-council-meetings/2023-07-11%20Annotated%20Agenda%20-%20Council.pdf

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.